Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. CMND
stocks logo

CMND

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Valuation Metrics

The current forward P/E ratio for Clearmind Medicine Inc (CMND.O) is 0.00, compared to its 5-year average forward P/E of 0.00. For a more detailed relative valuation and DCF analysis to assess Clearmind Medicine Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
0.00
Current PE
0.00
Overvalued PE
0.00
Undervalued PE
0.00

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

CMND News & Events

Events Timeline

(ET)
2025-12-04
11:00:00
Clearmind Doses First Participant with CMND-100 at Hadassah Medical Center
select
2025-12-02 (ET)
2025-12-02
08:00:00
Clearmind Medicine Enrolls First Participant in Phase I/IIa Trial for CMND-100 in Israel
select
2025-12-01 (ET)
2025-12-01
09:00:00
Clearmind Achieves Three Milestones in FDA-Approved CMND-100 Clinical Trial
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
11-26Benzinga
What Caused Clearmind Medicine's Shares to Rise 7% in Pre-Market Trading?

  • Stock Performance: Clearmind Medicine Inc. (CMND) saw a 7.09% increase in pre-market trading, reaching $0.1713, despite a 19.4% drop to $0.16 on Tuesday. The stock has fallen 88.97% this year, with a market cap of $5.26 million.

  • Clinical Trial Update: The company announced that the Tel Aviv Sourasky Medical Center enrolled the first participant in its Phase I/IIa clinical trial for CMND-100, a treatment for alcohol use disorder, which is FDA-approved.

  • Trial Network Expansion: TASMC joins other prestigious institutions like Yale and Johns Hopkins in the trial, with Prof. David Zeltser as the Principal Investigator overseeing the study.

  • Trial Results and Executive Statement: Initial results from the trial showed no significant adverse events, and CEO Dr. Adi Zuloff-Shani emphasized the importance of this milestone in accelerating their global trial efforts.

[object Object]
Preview
9.0
11-25Newsfilter
Clearmind Initiates Patient Recruitment for CMND-100 Clinical Trial at Leading Israeli Site
  • Clinical Trial Launch: Clearmind Medicine successfully recruits the first patient at Tel Aviv Sourasky Medical Center, marking the full activation of its FDA-approved multinational Phase I/IIa trial for CMND-100, which is expected to accelerate global enrollment and enhance the company's competitiveness in the psychedelic medicine sector.
  • Research Collaboration Expansion: TASMC joins a network of world-class centers including Yale School of Medicine, Johns Hopkins University School of Medicine, and Hadassah Medical Center, forming a robust patient screening and enrollment network that further amplifies Clearmind's influence in global clinical research.
  • Safety Validation: The first completed cohort of CMND-100 demonstrates excellent safety and adherence with no serious adverse events, providing a solid foundation for subsequent clinical trials and potentially positioning the drug as a breakthrough therapy for Alcohol Use Disorder.
  • Strategic Development Focus: The recruitment of the first patient not only represents a significant advancement in Clearmind's global trial but also reflects the company's strategic goal of developing novel neuroplasticity drugs aimed at addressing under-treated health issues, thereby enhancing its market position in the biotechnology field.
[object Object]
Preview
9.0
11-24Newsfilter
Clearmind Medicine's CMND-100 Clinical Trial Receives DSMB Recommendation
  • Clinical Trial Progress: Clearmind Medicine's CMND-100 has received a recommendation from the independent Data and Safety Monitoring Board (DSMB) to continue its FDA-approved Phase I/IIa clinical trial for treating Alcohol Use Disorder (AUD). The interim review showed a favorable safety profile with no serious adverse events reported, indicating good tolerability among participants.
  • Therapeutic Potential: CMND-100 is a non-hallucinogenic neuroplastogen aimed at reducing cravings and consumption in individuals with moderate to severe AUD. The DSMB's endorsement highlights its potential as a breakthrough therapy, potentially addressing the needs of millions affected worldwide.
  • Team Contributions: CEO Dr. Adi Zuloff-Shani noted that the trial's success is attributed to the contributions of clinical sites and participants, which are crucial for advancing the drug's development. The company plans to accelerate enrollment to push this innovative treatment forward.
  • Intellectual Property Strategy: Clearmind currently holds 19 patent families, including 31 granted patents, and intends to seek additional patents to strengthen its intellectual property portfolio. This strategy will position the company favorably in the rapidly evolving psychedelic pharmaceutical market.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Clearmind Medicine Inc (CMND) stock price today?

The current price of CMND is 0.1322 USD — it has increased 18.9 % in the last trading day.

arrow icon

What is Clearmind Medicine Inc (CMND)'s business?

Clearmind Medicine Inc. is a psychedelic pharmaceutical biotech company. The Company is focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorders. The Company researches and develops psychedelic-based compounds and attempts to commercialize them as regulated medicines, foods, or supplements. The Company’s intellectual portfolio consists of 19 patent families including 31 granted patents.

arrow icon

What is the price predicton of CMND Stock?

Wall Street analysts forecast CMND stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CMND is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Clearmind Medicine Inc (CMND)'s revenue for the last quarter?

Clearmind Medicine Inc revenue for the last quarter amounts to -1.41M USD, decreased -5.38 % YoY.

arrow icon

What is Clearmind Medicine Inc (CMND)'s earnings per share (EPS) for the last quarter?

Clearmind Medicine Inc. EPS for the last quarter amounts to -1084838.00 USD, decreased -3.72 % YoY.

arrow icon

What changes have occurred in the market's expectations for Clearmind Medicine Inc (CMND)'s fundamentals?

The market is revising No Change the revenue expectations for CMND for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -87.17%.
arrow icon

How many employees does Clearmind Medicine Inc (CMND). have?

Clearmind Medicine Inc (CMND) has 4 emplpoyees as of December 05 2025.

arrow icon

What is Clearmind Medicine Inc (CMND) market cap?

Today CMND has the market capitalization of 5.44M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free